Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 40Breast Neoplasms 40Prostatic Neoplasms 24Colorectal Neoplasms 24Uterine Cervical Neoplasms 16Carcinoma, Non-Small-Cell Lung 14Anxiety Disorders 13Stomach Neoplasms 9Lymphoma, Follicular 9Lung Neoplasms 9Leukemia, Myeloid, Acute 9Carcinoma, Hepatocellular 8Brain Neoplasms 8Urinary Bladder Neoplasms 7Sarcoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Head and Neck Neoplasms 7Esophageal Squamous Cell Carcinoma 7Esophageal Neoplasms 7Ovarian Neoplasms 6Epilepsy 6Depression 6Colonic Neoplasms 6Uterine Cervical Dysplasia 5Small Cell Lung Carcinoma 5Pain 5Glioma 5Dementia 5Cholangiocarcinoma 5Recurrence 4

Interventions

130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Interventional × TNBC × Clear all
NCT07376629 2026-01-29

A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Huabo Biopharm Co., Ltd.

Phase 2 Enrolling by invitation
60 enrolled
Breast

TNBC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡